Suneeta Reddy

We are pleased to report a strong performance within what is typically a seasonally weak quarter.

We are pleased to report a strong performance during what is typically a seasonally weak quarter.

We will continue to be able to maintain margins. We are carefully balancing the EBITDA deterioration in our new hospitals with how we are managing our existing hospitals.

We are quite confident that we will get back into 13% growth. Bangladesh, at least 60%, has started coming back in October, and we believe that we will mitigate the impact of losing one territory.

We are quite confident that we will get back into 13% growth... Bangladesh at least 60% has started coming back in October.

Our focus on specialties cardiac, oncology, neurosciences, gastro and orthopedics maintained a strong momentum growing revenues by 13%.

We are well on track to achieve break even in the digital business by the end of this fiscal.

We are well on track to achieve breakeven in the digital business by the end of this fiscal.

We have a plan to move it to 25%. As we look at the losses from new hospitals, total impact over a two-year period could maximum be around INR 150 crore.

We crossed INR 20,000 crore in consolidated revenue and came in at INR 21,794 crore. Alongside, healthcare services revenue crossed the milestone of INR 10,000 crore and came in at INR 11,147 crore.

We are on track to operationalize our previously announced facilities in Gurgaon, Pune, Kolkata, and Hyderabad later this fiscal year.

Our results reflect an all-around growth, with all three business segments reporting mid-teens revenue growth.